EGFR™ inhibitor, demonstrates preliminary anti-tumor activity across a variety of advanced EGFR-mutant non-small cell lung ...

Panelists discuss how understanding EGFR mutations has transformed the treatment landscape for non–small cell lung cancer ...

AI-driven nanomedicine advances enable personalized breast cancer treatments, combining precision, biomimetic nanocarriers, ...

Understand what the current ratio measures, why it matters, and how to use it to assess and improve short-term liquidity.

Patients with lupus nephritis who received hydroxychloroquine demonstrated a significantly lower risk for glomerular ...

Beverly is a writer, editor, and paralegal specializing in personal finance and tax law. She covers personal financial and legal topics, as well as tax breaks, tax preparation software, and tax law ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...

Investing.com -- Genmab A/S (CSE:GMAB) shares fell more than 3% on Monday after new data from Johnson & Johnson ’s amivantamab suggested the drug could rival Genmab and Merus N.V. ’s petosemtamab in ...

The biopharmaceutical company’s shares fell 3.53% in pre-market trading after the release. The company also announced plans to submit a Biologics License Application (BLA) for ivonescimab in the ...